INTRODUCTION AND OBJECTIVES: Salvage radiation therapy (SRT) represents a potential curative treatment option for patients affected by PSA rising after radical prostatectomy (RP). However, little is known about the risk of late recurrences and mortality after SRT. As such, we evaluated rates and predictors of late recurrences after SRT in a large, multi-institutional series of patients METHODS: The study included 161 patients who were alive and free from disease at 10 years after SRT. All patients received local radiation to the prostatic and seminal vesicle bed at seven tertiary referral centres. The outcomes consisted of biochemical recurrence (BCR), clinical recurrence (CR), cancer-specific mortality (CSM), and other-cause mortality (OCM) at 12, and 15 years after SRT. KaplanMeier method was used to assess oncological outcomes at different time points. Cumulative incidence Poisson smoothed plot was fitted to compare CSM and OCM rates. Multivariable Cox regression analysis tested the predictors of cancer recurrence. Covariates consisted of pT stage, pathological Gleason score, PSA level at SRT, patient age, and time from RP to SRT RESULTS: Median age at SRT was 66 years. The number of patients at risk for survival analyses at 10, 12, and 15 years was 161, 64, and 23, respectively. Overall, 13 patients developed BCR after 10 year of follow-up. Two of them developed CR and died of prostate cancer. Conversely, 14 men succumb to death from other causes. At 12-, and 15-yr after SRT, BCR-free survival rates were 93%, and 79%, whereas CR-free survival rates were 98%, and 97%, respectively. CSM rates were 1.6%, and 3.3%, whereas OCM rates were 4.3%, and 13.5% (Figure 1) . At multivariable analysis, pathological stage !pT3b was the only significant predictor of late BCR (HR: 3.97, p[0.046) CONCLUSIONS: We reported the risk of late recurrence and mortality of patients who were alive and free from disease at 10 years after SRT. Approximately one out of five patients still experienced late BCR. However, the risk of these patients to develop CR and to die from PCa was extremely low, suggesting that BCR after 10 years from SRT have mainly indolent course. Advanced stage at RP was the only significant predictor of late recurrence in this setting Source of Funding: None
PD15-06 RATES AND PATTERNS OF METASTASES IN PATIENTS WITH NODE-NEGATIVE PROSTATE CANCER AT RADICAL PROSTATECTOMY THAT EXPERIENCE PSA FAILURE: POST-HOC ANALYSIS OF RTOG 9601 TRIAL DATA
Akshay Sood*, Jacob Keeley, Sohrab Arora, Deepansh Dalela, Wooju Jeong, Craig G. Rogers, James Peabody, Mani Menon, Firas Abdollah, Detroit, MI INTRODUCTION AND OBJECTIVES: To evaluate rates and patterns of local and metastatic disease occurrence in patients with node-negative non-metastatic prostate cancer at radical prostatectomy (RP) that experience PSA elevation (recurrence or persistence) and undergo salvage radiation therapy (sRT).
METHODS: All available demographic, tumor-specific, treatment-specific, and local and metastatic disease occurrence data from 760 men who participated in the RTOG 9601 trial were extracted using the Project Data Sphere platform. Patients were stratified into PSA recurrence (post-RP PSA nadir <0.5 ng/ml) or PSA persistence (post-RP PSA nadir [>0.5 ng/ml) groups, based on cutoffs reported in the original trial. Inverse probability of treatment weighting (IPTW) analysis was utilized to minimize the baseline differences among the groups. Competing risk analysis tested the impact of PSA persistence versus recurrence on local and metastatic disease in IPTWadjusted model. RESULTS: Patients that experienced PSA persistence had higher Gleason grade disease (p[0.027), more advanced pathological stage (p[0.024), and higher PSA levels at the time of receipt of salvage therapy (p<0.001; Table 1 ). All patients received sRT, and approximately 50% of the patients in each group received concomitant anti-androgen therapy (p[0.951; Table 1 ). The median follow-up was 12 yrs. In the IPTW-adjusted cohort, the 10-yr local recurrence rates were 3.2% versus 1.4% in patients with persistent versus recurrent PSA (Gray test p[0.0001; Figure 1b) . Similarly, 10-yr metastatic recurrence rates were 28.6% versus 10.1% in patients with persistent versus recurrent PSA (Gray test p<0.0001; Figure 1a) . CONCLUSIONS: Patients with PSA persistence after RP are approximately 2.5 times more likely to experience local and metastatic disease, when compared to patients with PSA recurrence after RP, despite local sRT with/without anti-androgen therapy. These data may facilitate patient counseling and shared treatment selection.
